SuperBAC

May 4, 2022

Reading Time: 2 minutes SuperBac, a Leading Biotech Company in Brazil, Plans to List on Nasdaq through a Business Combination with XPAC Ochman Advogados represented SuperBac Biotechnology Solutions S.A., a Brazilian leading biotechnology company, as its Brazilian legal counsel in a de-Spac transaction with XPAC Acquisition Corp, a publicly-traded special purpose acquisition company based in the United States. Founded in 1995 by Luis Chacon , SuperBAC is a biotechnology solutions company with the purpose of promoting sustainability in the production processes of agribusiness, sanitation, energy, bioremediation and retail. The merger with XPAC Acquisition Corp will enable the company to be listed in the NASDAQ Stock Exchange. The combined company is expected to have a pro forma implied equity value post-money of approximately US$500 million (assuming a US$10.00 per share price). Details of the Transaction in Marketscreener.com . The Esquires and the Firms Behind the Deal